Advertisement
The leader in healthcare business news, research & data

Healthcare Economics

Generic-drug approval growth doesn't spark competition

Generic-drug approval growth doesn't spark competition

The first three generics introduced make the biggest dent on prices. But the vast majority of generic-drug approvals from 2012 to 2017 were for the fourth, fifth, sixth or even later versions that minimally impact prices, according to a new report.

Advertisement
X

Subscribe and SAVE 50%

View our best offer
Subscribe to Print